Godin Lab


Biana Godin (Vilentchouk), PhD, MScPharm
Assistant Professor of Nanomedicine
Houston Methodist Academic Institute

Dr. Godin Vilentchouk is one of the key team members on two multicenter, multi-investigator National Institutes of Health (NIH) National Cancer Institute grants: Physical Science in Oncology and the Center for Cancer Nanotechnology Excellence.

She is a principal investigator (PI) on a Telemedicine and Advanced Technology Research Center/Department of Defense (TATRC/DoD) seed-grant and two NIH pilot projects. Dr. Godin Vilentchouk's research interests also include nanomedicine applications in cardiology and infectious diseases.

About Our Lab

Dr. Godin's research focuses primarily on the following four areas:

 

  • Targeting liver metastasis with advanced nanocarriers
  • Physical sciences in oncology
  • Novel strategies to target tumor microenvironment
  • Nanovectors for improved treatment of infectious diseases

 

The main objective of these studies is to provide innovative approaches to cancer treatment and diagnosis.

10,289

Citations

47

h-index

Our Research

Research Projects Supported by Extramural Funding

  • Texas Center for Cancer Nanomedicine

    National Cancer Institute / National Institute of Health (09/01/2010-07/31/2015)

    The Texas Center for Cancer Nanomedicine (TCCN) aims to use innovative nanotechnologies for new therapeutic strategies, methodologies for reliable monitoring of therapeutic efficacy, early detection approaches from biological fluids and advances in radiological imaging, and cancer-prevention protocols for ovarian and pancreatic cancers.

  • Center for Transport Oncophysics

    National Institute of Health (09/28/2009-07/31/2014)

    This project aims to integrate physical sciences with nanotechnology. The Center for Transport Oncophysics (CTO) is a collaborative program among five institutions.

  • Tuning geometry of the therapeutic nanovectors and thioaptamer targeting: a dual approach to improve the efficacy of anti-tuberculosis treatment

    TATRC, DoD (B. Godin/ D. Gorenstein/ E. Gravis) (09/30/2011-09/30/2013)

    This project is exploring a new approach to highly improve treatment of tuberculosis with a dual targeting of therapeutic nanovectors to the infection loci. Our The strategy is based on (1) tuning the nanovector geometry for preferential uptake by macrophages and accumulation in the lungs based on the blood hemodynamics in the organ and (2) employing thioaptamers/X-aptamers ligands for targeting the infected macrophage population, as well as the pathogen-related microenvironment.

Research in Methodology

Clinical Research in Methodology
Read More Methodology Stories